Works matching DE "EMPAGLIFLOZIN"

Results: 1071

Stability Indicating Rp-Hplc for Method Development and Validation for Simultaneous Estimation of Empagliflozin and Nateglinide in Bulk Drug.

Published in:

Jordan Journal of Pharmaceutical Sciences, 2025, v. 18, n. 2, p. 538, doi. 10.35516/jjps.v18i2.2648

By:

Kajol;
Kaushik, Aditi;
Sharma, Nikhil

Publication type:

Article

Empagliflozin Repurposing for Lafora Disease: A Pilot Clinical Trial and Preclinical Investigation of Novel Therapeutic Targets.

Published in:

Methods & Protocols, 2025, v. 8, n. 3, p. 48, doi. 10.3390/mps8030048

By:

d'Orsi, Giuseppe;
Liantonio, Antonella;
Imbrici, Paola;
Gambacorta, Nicola;
Dinoi, Giorgia;
Altomare, Cosimo Damiano;
Carella, Massimo

Publication type:

Article

Keep your guard up: blood–brain barrier protection by empagliflozin after acute ischaemic stroke Free.

Published in:

Cardiovascular Research, 2025, v. 121, n. 5, p. 694, doi. 10.1093/cvr/cvaf049

By:

Hochrainer, Karin;
Hansen, Ashley;
Garcia-Bonilla, Lidia

Publication type:

Article

Efficacy of Hypoglycemic Agents in Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD): A Systematic Review and Network Meta‐Analysis.

Published in:

Journal of Evidence-Based Medicine, 2025, v. 18, n. 2, p. 1, doi. 10.1111/jebm.70021

By:

Ren, Qiao;
Tan, Yao;
Zhang, Guixiang;
Dai, Yuzhao;
Yang, Lidan;
Wu, Yunmo;
He, He;
Chen, Jie

Publication type:

Article

Bioequivalence Study of Two Empagliflozin Tablets in Healthy Chinese Subjects Under Fasting and Fed Conditions.

Published in:

Clinical Pharmacology in Drug Development, 2025, v. 14, n. 7, p. 542, doi. 10.1002/cpdd.1530

By:

Lei, Yuyan;
Liu, Yuan;
Gao, Lichen;
Peng, Xueqiong;
Chen, Lulu;
Li, Chao;
Chen, Weiming;
Xu, Junmei;
Ouyang, Dongsheng;
Li, Xiaohui

Publication type:

Article

Inhibition of the Na+-glucose transporter SGLT2 reduces glucose uptake and IFNγ release from activated human CD4+ T cells.

Published in:

Frontiers in Immunology, 2025, p. 1, doi. 10.3389/fimmu.2025.1576216

By:

Jin, Zhe;
Hammoud, Hayma;
Bhandage, Amol K.;
Koreli, Stasini;
Chowdhury, Azazul Islam;
Bergsten, Peter;
Birnir, Bryndis

Publication type:

Article

The SGLT2 Inhibitor Empagliflozin Mitigates the Harmful Effects of Methylglyoxal Exposure on Ovalbumin-Induced Mouse Airway Inflammation.

Published in:

International Journal of Molecular Sciences, 2025, v. 26, n. 12, p. 5753, doi. 10.3390/ijms26125753

By:

Medeiros, Matheus L.;
Oliveira, Akila L.;
Antunes, Edson

Publication type:

Article

Sodium-Glucose Cotransporter 2 Inhibitors, Erythrocytosis, and Thrombosis in Adults With Type 2 Diabetes.

Published in:

JAMA Network Open, 2025, v. 8, n. 6, p. e2517086, doi. 10.1001/jamanetworkopen.2025.17086

By:

Lewis, Maor;
Burrack, Nitzan;
Heymann, Anthony;
Grossman, Alon;
Neuman, Tsipora;
Abuhasira, Ran

Publication type:

Article

Breaking news in cardiovascular outcome trials; empagliflozin and stroke; and glycaemic variability in type 1 diabetes.

Published in:: Journal of Diabetes Nursing, 2017, v. 21, n. 6, p. 223
Publication type:: Article

CANVAS and EMPA-REG findings support cardiovascular safety of SGLT2 inhibitors.

Published in:

Journal of Diabetes Nursing, 2017, v. 21, n. 6, p. 193

By:

Hill, Jill

Publication type:

Article

Keeping abreast of the latest diabetes research: HbA1c screening, older people and empagliflozin.

Published in:

Journal of Diabetes Nursing, 2016, v. 20, n. 1, p. 38

By:

Dunning, Trisha

Publication type:

Article

Expect the Unexpected: SGLT-2 Inhibitors in the Treatment of Type 2 Diabetes and/or Heart Failure.

Published in:

Cardiology, 2020, v. 145, n. 5, p. 321, doi. 10.1159/000506731

By:

Seferovic, Jelena P.;
Seferovic, Petar M.

Publication type:

Article

The effect of low and high dose empagliflozin on HbA1c and lipid profile in type 2 diabetes mellitus: A real-world data.

Published in:

Northern Clinics of Istanbul, 2020, v. 7, n. 2, p. 167, doi. 10.14744/nci.2019.22697

By:

Ozcelik, Serhat;
Celik, Mehmet;
Vural, Aski;
Aydin, Bunyamin

Publication type:

Article

Clinician's guide for empagliflozin use in heart failure.

Published in:

Folia Cardiologica, 2022, v. 17, n. 4, p. 226, doi. 10.5603/FC.a2022.0023

By:

Lelonek, Małgorzata

Publication type:

Article

A report from the American Heart Association Scientific Sessions 2021.

Published in:

Folia Cardiologica, 2022, v. 17, n. 3, p. 199, doi. 10.5603/FC.2022.0037

By:

Polańska, Anna;
Kasprzak, Jarosław D.

Publication type:

Article

Sodium-glucose co-transporter 2 inhibitors therapy: not only for diabetologists.

Published in:

Folia Cardiologica, 2021, v. 16, n. 6, p. 389, doi. 10.5603/FC.2021.0057

By:

Sawościan, Maria;
Lelonek, Małgorzata

Publication type:

Article

Survey to Specify SGLT2 Inhibitor Choice in T2DM Management.

Published in:

Clinical Diabetology, 2022, v. 11, n. 5, p. 326, doi. 10.5603/DK.a2022.0042

By:

Ghosal, Samit;
Joshi, Radhika M.;
Iyer, Rahul N.;
Adsule, Samir M.

Publication type:

Article

Euglycemic diabetic ketoacidosis associated with empagliflozin in patients hospitalized with acute pulmonary embolism.

Published in:

Clinical Diabetology, 2021, v. 10, n. 2, p. 204, doi. 10.5603/DK.a2021.0010

By:

Wibawa, Kevin;
Kuhuwael, Ferica Valentine;
Julyanto Putra, Caesar Rio;
Utami Widiastuti, Sandra;
Paskah Suciadi, Leonardo

Publication type:

Article

Green and white MEKC for determination of different anti-diabetic binary mixtures and their triple-combo pill.

Published in:

BMC Chemistry, 2023, v. 17, n. 1, p. 1, doi. 10.1186/s13065-023-00997-0

By:

Ahmed, Aya R.;
Korany, Mohamed A.;
Galal, Shereen M.;
Ragab, Marwa A. A.

Publication type:

Article

HPLC-DAD technique for the quantification of a recently approved anti-diabetic triple combination along with two toxic official impurities: Toxicity confirmation aided by molecular docking application.

Published in:

BMC Chemistry, 2023, v. 17, n. 1, p. 1, doi. 10.1186/s13065-023-00927-0

By:

Bahgat, Eman A.;
Hashem, Hisham;
Saleh, Hanaa;
Kamel, Ebraam B.;
Eissa, Maya S.

Publication type:

Article

Glucometabolic Efficacy of the Empagliflozin/Metformin Combination in People with Type 1 Diabetes and Increased Cardiovascular Risk: A Sub-Analysis of a Pilot Randomized Controlled Trial.

Published in:

Journal of Clinical Medicine, 2024, v. 13, n. 22, p. 6860, doi. 10.3390/jcm13226860

By:

Janić, Miodrag;
Janež, Andrej;
Šabović, Mišo;
El-Tanani, Mohamed;
Rangraze, Imran;
Rizzo, Manfredi;
Lunder, Mojca

Publication type:

Article

Safety and Tolerability of SGLT2 Inhibitors in Cardiac Amyloidosis—A Clinical Feasibility Study.

Published in:

Journal of Clinical Medicine, 2024, v. 13, n. 1, p. 283, doi. 10.3390/jcm13010283

By:

Steinhardt, Maximilian J.;
Cejka, Vladimir;
Chen, Mengmeng;
Bäuerlein, Sabrina;
Schäfer, Julia;
Adrah, Ali;
Ihne-Schubert, Sandra M.;
Papagianni, Aikaterini;
Kortüm, K. Martin;
Morbach, Caroline;
Störk, Stefan

Publication type:

Article

Empagliflozin Reduces Interleukin-6 Levels in Patients with Heart Failure.

Published in:

Journal of Clinical Medicine, 2023, v. 12, n. 13, p. 4458, doi. 10.3390/jcm12134458

By:

Gotzmann, Michael;
Henk, Pauline;
Stervbo, Ulrik;
Blázquez-Navarro, Arturo;
Mügge, Andreas;
Babel, Nina;
Westhoff, Timm H.

Publication type:

Article

Sodium Glucose Cotransporter-2 Inhibitor Empagliflozin Increases Antioxidative Capacity and Improves Renal Function in Diabetic Rats.

Published in:

Journal of Clinical Medicine, 2023, v. 12, n. 11, p. 3815, doi. 10.3390/jcm12113815

By:

Yaribeygi, Habib;
Hemmati, Mohammad Amin;
Nasimi, Fatemeh;
Maleki, Mina;
Jamialahmadi, Tannaz;
Reiner, Ivan;
Reiner, Željko;
Sahebkar, Amirhossein

Publication type:

Article

The Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitor Empagliflozin Reverses Hyperglycemia-Induced Monocyte and Endothelial Dysfunction Primarily through Glucose Transport-Independent but Redox-Dependent Mechanisms.

Published in:

Journal of Clinical Medicine, 2023, v. 12, n. 4, p. 1356, doi. 10.3390/jcm12041356

By:

Semo, Dilvin;
Obergassel, Julius;
Dorenkamp, Marc;
Hemling, Pia;
Strutz, Jasmin;
Hiden, Ursula;
Müller, Nicolle;
Müller, Ulrich Alfons;
Zulfikar, Sajan Ahmad;
Godfrey, Rinesh;
Waltenberger, Johannes

Publication type:

Article

Mechanistic View on the Effects of SGLT2 Inhibitors on Lipid Metabolism in Diabetic Milieu.

Published in:

Journal of Clinical Medicine, 2022, v. 11, n. 21, p. 6544, doi. 10.3390/jcm11216544

By:

Yaribeygi, Habib;
Maleki, Mina;
Reiner, Željko;
Jamialahmadi, Tannaz;
Sahebkar, Amirhossein

Publication type:

Article

Efficacy and Safety of Empagliflozin in Type 2 Diabetes Mellitus Saudi Patients as Add-On to Antidiabetic Therapy: A Prospective, Open-Label, Observational Study.

Published in:

Journal of Clinical Medicine, 2022, v. 11, n. 16, p. 4769, doi. 10.3390/jcm11164769

By:

Althobaiti, Fahad M.;
Alsanosi, Safaa M.;
Falemban, Alaa H.;
Alzahrani, Abdullah R.;
Fataha, Salma A.;
Salih, Sara O.;
Alrumaih, Ali M.;
Alotaibi, Khalid N.;
Althobaiti, Hazim M.;
Al-Ghamdi, Saeed S.;
Ayoub, Nahla

Publication type:

Article

Effects of SGLT2 Inhibitors on Atherosclerosis: Lessons from Cardiovascular Clinical Outcomes in Type 2 Diabetic Patients and Basic Researches.

Published in:

Journal of Clinical Medicine, 2022, v. 11, n. 1, p. 137, doi. 10.3390/jcm11010137

By:

Xu, Jing;
Hirai, Taro;
Koya, Daisuke;
Kitada, Munehiro

Publication type:

Article

Efficacy and Safety of Empagliflozin Continuation in Patients with Type 2 Diabetes Hospitalised for Acute Decompensated Heart Failure.

Published in:

Journal of Clinical Medicine, 2021, v. 10, n. 16, p. 3540, doi. 10.3390/jcm10163540

By:

Pérez-Belmonte, Luis M.;
Ricci, Michele;
Sanz-Cánovas, Jaime;
Millán-Gómez, Mercedes;
Osuna-Sánchez, Julio;
Ruiz-Moreno, M. Isabel;
Bernal-López, M. Rosa;
López-Carmona, María D.;
Jiménez-Navarro, Manuel;
Gómez-Doblas, Juan J.;
Lara, José P.;
Gómez-Huelgas, Ricardo

Publication type:

Article

Safety and Efficacy of SGLT2 Inhibitors: A Multiple-Treatment Meta-Analysis of Clinical Decision Indicators.

Published in:

Journal of Clinical Medicine, 2021, v. 10, n. 12, p. 2713, doi. 10.3390/jcm10122713

By:

Martínez-Vizcaíno, Vicente;
Díez-Fernández, Ana;
Álvarez-Bueno, Celia;
Martínez-Alfonso, Julia;
Cavero-Redondo, Iván

Publication type:

Article

The SGLT2 Inhibitor Empagliflozin Ameliorates the Inflammatory Profile in Type 2 Diabetic Patients and Promotes an Antioxidant Response in Leukocytes.

Published in:

Journal of Clinical Medicine, 2019, v. 8, n. 11, p. 1814, doi. 10.3390/jcm8111814

By:

Iannantuoni, Francesca;
M. de Marañon, Aranzazu;
Diaz-Morales, Noelia;
Falcon, Rosa;
Bañuls, Celia;
Abad-Jimenez, Zaida;
Victor, Victor M.;
Hernandez-Mijares, Antonio;
Rovira-Llopis, Susana

Publication type:

Article

Empagliflozin Alleviates Carfilzomib-Induced Cardiotoxicity in Mice by Modulating Oxidative Stress, Inflammatory Response, Endoplasmic Reticulum Stress, and Autophagy.

Published in:

Antioxidants, 2024, v. 13, n. 6, p. 671, doi. 10.3390/antiox13060671

By:

George, Mina Y.;
Dabour, Mohamed S.;
Rashad, Eman;
Zordoky, Beshay N.

Publication type:

Article

Effect of Empagliflozin on Thioacetamide-Induced Liver Injury in Rats: Role of AMPK/SIRT-1/HIF-1α Pathway in Halting Liver Fibrosis.

Published in:

Antioxidants, 2022, v. 11, n. 11, p. 2152, doi. 10.3390/antiox11112152

By:

ElBaset, Marwan A.;
Salem, Rana S.;
Ayman, Fairouz;
Ayman, Nadeen;
Shaban, Nooran;
Afifi, Sherif M.;
Esatbeyoglu, Tuba;
Abdelaziz, Mahmoud;
Elalfy, Zahraa S.

Publication type:

Article

Effects of sodium-glucose transporter-2 inhibition on systemic hemodynamics, renal function, and intra-renal oxygenation in sepsis-associated acute kidney injury.

Published in:

Intensive Care Medicine Experimental, 2024, v. 12, n. 1, p. 1, doi. 10.1186/s40635-024-00647-2

By:

Hulst, Abraham H.;
Ow, Connie P. C.;
May, Clive N.;
Hood, Sally H.;
Plummer, Mark P.;
Hermanides, Jeroen;
van Raalte, Daniël H.;
Deane, Adam M.;
Bellomo, Rinaldo;
Lankadeva, Yugeesh R.

Publication type:

Article

Micro- and Macrovascular Complications in Diabetes Mellitus: Preclinical and Clinical Studies.

Published in:

Journal of Diabetes Research, 2019, p. 1, doi. 10.1155/2019/2161085

By:

Rangel, Érika B.;
Rodrigues, Cláudia O.;
de Sá, João R.

Publication type:

Article

Hiponatremiye Klinik Yaklaşım ve Tedavi Seçenekleri: Tek Merkez Deneyimi.

Published in:

Journal of Ankara University Faculty of Medicine / Ankara Üniversitesi Tip Fakültesi Mecmuasi, 2023, v. 76, n. 3, p. 195, doi. 10.4274/atfm.galenos.2023.72692

By:

Eren, Şayeste Akkan;
Kumru, Gizem;
Keven, Kenan

Publication type:

Article

Empagliflozin reduces podocyte lipotoxicity in experimental Alport syndrome.

Published in:

eLife, 2023, p. 1, doi. 10.7554/eLife.83353

By:

Mengyuan Ge;
Molina, Judith;
Jin-Ju Kim;
Mallela, Shamroop K.;
Ahmad, Anis;
Santos, Javier Varona;
Al-Ali, Hassan;
Mitrofanova, Alla;
Sharma, Kumar;
Fontanesi, Flavia;
Merscher, Sandra;
Fornoni, Alessia

Publication type:

Article

Comparative Study of Three Brands of Antidiabetic Drug, Empagliflozin Available in Karachi, Pakistan.

Published in:

Journal of University Medical & Dental College, 2023, v. 14, n. 2, p. 626, doi. 10.37723/jumdc.v14i2.781

By:

Aslam, Khadija;
Naveed, Safila;
Qamar, Fatima;
Sadia, Halima;
Khan, Muhammad Ulusyar;
Aman, Tajala

Publication type:

Article

Empagliflozin attenuates doxorubicin-induced cardiotoxicity.

Published in:

Toxicology Research, 2023, v. 12, n. 5, p. 998, doi. 10.1093/toxres/tfad071

By:

Barış, Veysel Özgür;
Dinçsoy, Adnan Berk;
Gedikli, Esra;
Zırh, Selim;
Müftüoğlu, Sevda;
Erdem, Ayşen

Publication type:

Article

Empagliflozin attenuates doxorubicin-induced cardiotoxicity by activating AMPK/SIRT-1/PGC-1α-mediated mitochondrial biogenesis.

Published in:

Toxicology Research, 2023, v. 12, n. 2, p. 216, doi. 10.1093/toxres/tfad007

By:

Chen, Meicong

Publication type:

Article

The real-world safety profile of empagliflozin: a disproportionality analysis based on the FDA Adverse Event Reporting System (FAERS) database.

Published in:

BMC Pharmacology & Toxicology, 2025, v. 26, n. 1, p. 1, doi. 10.1186/s40360-025-00861-y

By:

Hu, Huiping;
Liu, Maochang;
Fu, Zhiwen;
Li, Shijun;
Wang, Kaiping;
Huang, Zi

Publication type:

Article

Traditional Medicine and Its Impact on Patient Outcomes in Type 2 Diabetes Mellitus Therapy.

Published in:

Indonesian Journal of Pharmacy / Majalah Farmasi Indonesia, 2022, v. 33, n. 4, p. 621

By:

Faridah, Imaniar Noor;
Perwitasari, Dyah Aryani;
Maer, Khoirunnisa;
Octapermatasari, Resti;
Novitasari, Laras

Publication type:

Article

Pharmacokinetic Comparison Between a Fixed‐Dose Combination of Empagliflozin L‐Proline/Metformin and Empagliflozin/Metformin in Healthy Korean Subjects.

Published in:

Clinical Pharmacology in Drug Development, 2023, v. 12, n. 12, p. 1156, doi. 10.1002/cpdd.1310

By:

Lee, HyunJoon;
Chung, Jae‐Yong;
Yu, Kyung‐Sang;
Park, Shin‐Jung;
Lee, Soyoung

Publication type:

Article

Validation of an Announced Telephone Pill Count Compared to a Home‐Visit Pill Count in People With Type 2 Diabetes or Cardiovascular Disease.

Published in:

Clinical Pharmacology in Drug Development, 2023, v. 12, n. 1, p. 85, doi. 10.1002/cpdd.1185

By:

Langendoen‐Gort, Marlous;
Rutters, Femke;
Huijts, Daniëlle;
Elders, Petra JM;
Terwee, Caroline B.;
Hugtenburg, Jacqueline G.

Publication type:

Article

The effects of empagliflozin in patients with type 1 diabetes: Results of a 12-week, double-blind, randomized, placebo-controlled clinical trial.

Published in:

Health Promotion Perspectives, 2024, v. 14, n. 4, p. 380, doi. 10.34172/hpp.42486

By:

Najafipour, Mostafa;
Najafipour, Farzad;
Ostadrahimi, Alireza;
Ghavami, Maryam;
Razaghi, Zohreh;
Tutunchi, Helda;
Mesri Alamdari, Naimeh

Publication type:

Article

Drug-induced urinary retention: a real-world pharmacovigilance study using FDA and Canada vigilance databases.

Published in:

Frontiers in Pharmacology, 2025, p. 1, doi. 10.3389/fphar.2024.1466875

By:

Dai, Xianyu;
Yu, Kai;
Chang, Yu;
Hou, Yuchuan

Publication type:

Article

Fasting and postprandial kidney haemodynamic effects of empagliflozin and linagliptin in mono‐ and combination therapy compared to gliclazide in overweight people with type 2 diabetes (RACELINES): A randomised, double‐blind trial.

Published in:

Diabetes, Obesity & Metabolism, 2025, v. 27, n. 7, p. 3943, doi. 10.1111/dom.16431

By:

van Baar, Michaël J. B.;
Muskiet, Marcel H. A.;
Scholtes, Rosalie A.;
Touw, Daan J.;
Nieuwdorp, Max;
Kramer, Mark H. H.;
Joles, Jaap A.;
Cherney, David Z. I.;
Bjornstad, Petter;
Krebber, Merle M.;
van Raalte, Daniël H.

Publication type:

Article

Empagliflozin versus DPP4i or GLP‐1RA for the risk of nephrolithiasis in patients with type 2 diabetes: Research letter from the EMPRISE cohort study.

Published in:

Diabetes, Obesity & Metabolism, 2025, v. 27, n. 6, p. 3503, doi. 10.1111/dom.16303

By:

Tesfaye, Helen;
Paik, Julie M.;
Zakoul, Heidi;
Schmedt, Niklas;
Wexler, Deborah J.;
Patorno, Elisabetta

Publication type:

Article

iGlarLixi effectively reduces residual hyperglycaemia in Chinese people with type 2 diabetes on basal insulin: A post hoc analysis of the LixiLan‐L‐CN study.

Published in:

Diabetes, Obesity & Metabolism, 2024, v. 26, n. 12, p. 5942, doi. 10.1111/dom.15968

By:

Yuan, Xiaoyong;
Li, Dongmei;
Wang, Kun;
Lauand, Felipe;
Zhang, Minlu;
Fang, Hexin;
Du, Qin;
Kang, Lei;
Alvarez, Agustina;
Guo, Xiaohui

Publication type:

Article

Medication adherence to sodium‐glucose cotransporter‐2 inhibitors versus glucagon‐like peptide‐1 receptor agonists: A meta‐analysis.

Published in:

Diabetes, Obesity & Metabolism, 2024, v. 26, n. 10, p. 4544, doi. 10.1111/dom.15809

By:

Johnson, Conner E.;
Sussman, Whitney B.;
Weeda, Erin R.

Publication type:

Article